Leveraging Biomarkers for Precision Medicine in Heart Failure.
作者信息
Kennedy Sharon Grossman, Gaggin Hanna K
机构信息
Harvard Medical School, Boston, MA; Department of Medicine, Massachusetts General Hospital.
Division of Cardiology, Corrigan Minehan Heart Center; Harvard Medical School, Boston, MA.
出版信息
J Card Fail. 2023 Apr;29(4):459-462. doi: 10.1016/j.cardfail.2023.03.001. Epub 2023 Mar 11.
Abstract
摘要
相似文献
1
Leveraging Biomarkers for Precision Medicine in Heart Failure.利用生物标志物实现心力衰竭的精准医学
J Card Fail. 2023 Apr;29(4):459-462. doi: 10.1016/j.cardfail.2023.03.001. Epub 2023 Mar 11.
2
Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action.从心力衰竭的常规治疗向基于生物标志物的个性化精准医学转变：行动呼吁。
Eur Heart J. 2018 Aug 7;39(30):2793-2799. doi: 10.1093/eurheartj/ehx027.
3
A Peek Into the Future: Will Serial Multimarker Testing Help Bring a New Era of Precision Medicine in Heart Failure Patients?展望未来：系列多标志物检测能否助力开启心力衰竭患者精准医疗的新时代？
Circ Heart Fail. 2023 Jan;16(1):e010156. doi: 10.1161/CIRCHEARTFAILURE.122.010156. Epub 2022 Nov 21.
4
Established and Emerging Roles of Biomarkers in Heart Failure Clinical Trials.生物标志物在心力衰竭临床试验中的既定作用与新兴作用
Circ Heart Fail. 2016 Sep;9(9). doi: 10.1161/CIRCHEARTFAILURE.115.002528.
5
Individualized Knowledge Graph: A Viable Informatics Path to Precision Medicine.个体化知识图谱：精准医学的可行信息学途径。
Circ Res. 2017 Mar 31;120(7):1078-1080. doi: 10.1161/CIRCRESAHA.116.310024.
6
Variations on a Precision Medicine Theme: One Size Fits Some.精准医学主题的变奏曲：一种尺码适合部分人。
Circ Heart Fail. 2016 Aug;9(8). doi: 10.1161/CIRCHEARTFAILURE.116.003021.
7
Clinical use of novel biomarkers in heart failure: towards personalized medicine.新型生物标志物在心力衰竭中的临床应用：迈向个性化医疗
Heart Fail Rev. 2014 May;19(3):369-81. doi: 10.1007/s10741-013-9396-5.
8
Timely Management of New-Onset Heart Failure.新发心力衰竭的及时管理
Circulation. 2019 Aug 20;140(8):621-623. doi: 10.1161/CIRCULATIONAHA.118.035452. Epub 2019 Aug 19.
9
Heart failure with preserved ejection fraction: towards an understanding of an enigma.射血分数保留的心力衰竭：迈向对一个谜团的理解。
Eur Heart J. 2019 Oct 21;40(40):3277-3280. doi: 10.1093/eurheartj/ehz756.
10
Myocardial interstitial fibrosis in the era of precision medicine. Biomarker-based phenotyping for a personalized treatment.精准医学时代的心肌间质纤维化。基于生物标志物的表型分析用于个性化治疗。
Rev Esp Cardiol (Engl Ed). 2020 Mar;73(3):248-254. doi: 10.1016/j.rec.2019.09.010. Epub 2019 Nov 20.
引用本文的文献
1
Beyond Natriuretic Peptides: Unveiling the Power of Emerging Biomarkers in Heart Failure.超越利钠肽：揭示心力衰竭新兴生物标志物的力量。
Biomolecules. 2024 Mar 6;14(3):309. doi: 10.3390/biom14030309.
2
Prognostic value of plasma secretoneurin concentration in patients with heart failure with reduced ejection fraction in one-year follow-up.在一年的随访中，心力衰竭射血分数降低患者血浆分泌素浓度的预后价值。
Ann Med. 2024 Dec;56(1):2305309. doi: 10.1080/07853890.2024.2305309. Epub 2024 Jan 23.
Zotero 插件